Ooferektomize ratlarda stronsiyum ranelat, raloksifen ve mizoprostolün kemik mineral dansitesi üzerine etkileri
Küçük Resim Yok
Tarih
2007
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada postmenopozal osteoporoz tedavisinde kullanılan stronsiyum ranelat, raloksifen ve mizoprostolün ooferektomize ratlarda kemik mineral dansitesi üzerine etkilerini araştırdık. Çalışmamızda 60 adet dişi Sprague-Dawley rat rastgele SR, MİZO, RAL, SHAM, DS ve OVX olmak üzere 6 gruba ayrıldı. Ratlara laparotomi uygulanarak bilateral ooferektomi yapıldı SHAM grubuna ooferektomi uygulanmadı. Operasyondan 3 gün sonra başlayarak SR grubuna 1800 mg/kg/gün stronsiyum ranelat, MİZO grubuna 200 ?g/kg/gün mizoprostol, RAL grubuna 3 mg/kg/gün raloksifen ve DS grubuna 1'er cc distile su mideye gavaj yoluyla uygulandı. 8 hafta sonra bütün grupların kemik mineral dansite ölçümleri yapıldı. Sonuçlar değerlendirildiğinde SHAM grubunun femur dansitesi OVX grubunun dansitesinden anlamlı derecede yüksek bulundu. SR grubunun femur dansitesi OVX ve DS grubunun femur dansitesine göre anlamlı derecede yüksek (p=0,001) ve SHAM grubunun dansitesiyle benzer olarak bulundu. MİZO, RAL, DS ve OVX gruplarının femur dansitesi arasında anlamlı fark bulunamadı (p>0,05) RAL ve MİZO gruplarının vertebra dansitesi SHAM, OVX ve DS gruplarının dansitesine göre ve yine SR grubunun vertebra dansitesi diğer tüm grupların dansitesine göre anlamlı derecede yüksek bulundu (p<0,001). SHAM grubunun total dansite değeri diğer grupların dansite değerlerine göre anlamlı derecede yüksek (p<0,001), SR grubunun total kemik dansite değeri OVX, DS, RAL ve MİZO dansite değerine göre anlamlı derecede artmış olarak tespit edildi. RAL ve MİZO gruplarının total kemik dansite değerleri benzer ve OVX grubunun kemik dansite değerine göre anlamlı derecede düşük bulundu. Çalışmamızın sonucunda stronsiyum ranelat, raloksifen ve mizoprostolün vertebrada, aynı zamanda stronsiyum ranelatın femurda da kemik kaybını önleyebileceğini tespit ettik. Vertebrada stronsiyum ranelatın raloksifen ve mizoprostole göre daha etkili olduğunu gözledik . Anahtar kelimeler: Osteoporoz, stronsiyum ranelat, raloksifen, prostaglandin.
We aimed to study the effects of strontium ranelate, raloxifene and misoprostol on bone mineral density of ovariectomized rats. Sixty female Sprague-Dawley rats were randomly divided into six groups: SR, MİZO, RAL, SHAM, DS and OVX. The rats were operated and all of them except SHAM rats were subjected to bilateral ovariectomy. Three days after surgery, SR rats were treated with 1800 mg/kg/day strontium ranelate, MİZO rats were treated with 200 ?g/kg/day misoprostol, RAL rats were treated with 3 mg/kg/day raloxifene and DS rats were treated with vehicle (1 cc of distilled water). Treatment was administered by gavage. After 8 weeks bone mineral density measurements were performed. As a result SHAM group femur density was significantly higher than OVX group. SR group femur density was significantly higher than OVX and DS groups (p=0.001) and there was no difference between femur density of SR and SHAM groups. There was no difference among femur density of MİZO, RAL, DS and OVX groups (p>0.05) . Vertebra bone mineral density of RAL and MİZO groups was significantly higher than that of SHAM, DS and OVX groups (p<0.001) while that of SR group was significantly higher than vertebrae density of all other groups. Total bone mineral density of SHAM group was significantly higher than that of all other groups (p<0.001). SR group had significantly higher total bone mineral density than that of OVX, DS, RAL and MİZO groups. RAL and MİZO groups had similar total density which was significantly lower than that of OVX and DS groups. In conclusion, these results indicate that strontium ranelate, raloxifene and misoprostol can prevent bone loss in the vertebrae, whereas strontium ranelate can also prevent bone loss in the femur of ovariectomized rats. Strontium ranelate increases bone mineral density of vertebrae greater than raloxifene and misoprostol. Key words: Osteoporosis, strontium ranelate, raloxifene, prostaglandins
We aimed to study the effects of strontium ranelate, raloxifene and misoprostol on bone mineral density of ovariectomized rats. Sixty female Sprague-Dawley rats were randomly divided into six groups: SR, MİZO, RAL, SHAM, DS and OVX. The rats were operated and all of them except SHAM rats were subjected to bilateral ovariectomy. Three days after surgery, SR rats were treated with 1800 mg/kg/day strontium ranelate, MİZO rats were treated with 200 ?g/kg/day misoprostol, RAL rats were treated with 3 mg/kg/day raloxifene and DS rats were treated with vehicle (1 cc of distilled water). Treatment was administered by gavage. After 8 weeks bone mineral density measurements were performed. As a result SHAM group femur density was significantly higher than OVX group. SR group femur density was significantly higher than OVX and DS groups (p=0.001) and there was no difference between femur density of SR and SHAM groups. There was no difference among femur density of MİZO, RAL, DS and OVX groups (p>0.05) . Vertebra bone mineral density of RAL and MİZO groups was significantly higher than that of SHAM, DS and OVX groups (p<0.001) while that of SR group was significantly higher than vertebrae density of all other groups. Total bone mineral density of SHAM group was significantly higher than that of all other groups (p<0.001). SR group had significantly higher total bone mineral density than that of OVX, DS, RAL and MİZO groups. RAL and MİZO groups had similar total density which was significantly lower than that of OVX and DS groups. In conclusion, these results indicate that strontium ranelate, raloxifene and misoprostol can prevent bone loss in the vertebrae, whereas strontium ranelate can also prevent bone loss in the femur of ovariectomized rats. Strontium ranelate increases bone mineral density of vertebrae greater than raloxifene and misoprostol. Key words: Osteoporosis, strontium ranelate, raloxifene, prostaglandins
Açıklama
Tıpta Uzmanlık
Anahtar Kelimeler
Kadın Hastalıkları ve Doğum, Obstetrics and Gynecology
